Life Science Innovation and the Restructuring of the Pharmaceutical Industry: Merger, Acquisition and Strategic Alliance Behaviour of Large Firms
Life Science Innovation and the Restructuring of the Pharmaceutical Industry: Merger, Acquisition and Strategic Alliance Behaviour of Large Firms
复制标题
生命科学创新与医药行业重组：大企业并购与战略联盟行为
DOI：
--
复制
发表时间：
2007
影响因子：
3.4
通讯作者：
James Mittra
中科院分区：
文献类型：
--
作者：
James Mittra
摘要本文探讨了生命科学在制药企业兼并、收购和战略联盟背景下的变革性质。根据对大型制药公司高级科学家和管理人员的采访以及有关一般行业趋势的二级数据，它确定了捕获和利用新技术/知识的不同公司战略，并探讨了它们对创新的影响。本文认为，合并，收购和战略联盟代表了一组相关的活动，提供了各种战略选择管理创新和生产力赤字。然而，由于内部研发和外部知识之间的平衡取决于公司的一些具体因素，以及外部经营环境带来的挑战，大公司之间在如何利用和战略管理这些活动方面的差异越来越大。
Abstract This article explores the transformative nature of the life sciences in the context of pharmaceutical mergers, acquisitions and strategic alliances. Drawing on interviews with senior scientists and managers from large pharmaceutical firms, and secondary data on general industry trends, it identifies diverse company strategies for capturing and exploiting new technologies/knowledge and explores their implications for innovation. The article suggests that mergers, acquisitions and strategic alliances represent a cluster of related activities that provide various strategic options for managing innovation and productivity deficit. However, because the preferred balance between in-house R&D and externally sourced knowledge depends on a number of firm-specific factors, as well as challenges posed by the external operating environment, there is increasing variation between large companies in how these activities are exploited and strategically managed.